Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy.

Triulzi T, Forte L, Regondi V, Di Modica M, Ghirelli C, Carcangiu ML, Sfondrini L, Balsari A, Tagliabue E.

Oncoimmunology. 2018 Sep 21;8(1):e1512942. doi: 10.1080/2162402X.2018.1512942. eCollection 2019.

2.

Modulation of Pulmonary Microbiota by Antibiotic or Probiotic Aerosol Therapy: A Strategy to Promote Immunosurveillance against Lung Metastases.

Le Noci V, Guglielmetti S, Arioli S, Camisaschi C, Bianchi F, Sommariva M, Storti C, Triulzi T, Castelli C, Balsari A, Tagliabue E, Sfondrini L.

Cell Rep. 2018 Sep 25;24(13):3528-3538. doi: 10.1016/j.celrep.2018.08.090.

3.

Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.

Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, Milione M, Porcu L, Proto C, Pruneri G, Signorelli D, Sangaletti S, Sfondrini L, Storti C, Tassi E, Bardelli A, Marsoni S, Torri V, Tripodo C, Colombo MP, Anichini A, Rivoltini L, Balsari A, Sozzi G, Garassino MC.

Clin Cancer Res. 2019 Feb 1;25(3):989-999. doi: 10.1158/1078-0432.CCR-18-1390. Epub 2018 Sep 11.

PMID:
30206165
4.

Exploiting poly(I:C) to induce cancer cell apoptosis.

Bianchi F, Pretto S, Tagliabue E, Balsari A, Sfondrini L.

Cancer Biol Ther. 2017 Oct 3;18(10):747-756. doi: 10.1080/15384047.2017.1373220. Epub 2017 Sep 7. Review.

5.

Activation of NK cell cytotoxicity by aerosolized CpG-ODN/poly(I:C) against lung melanoma metastases is mediated by alveolar macrophages.

Sommariva M, Le Noci V, Storti C, Bianchi F, Tagliabue E, Balsari A, Sfondrini L.

Cell Immunol. 2017 Mar;313:52-58. doi: 10.1016/j.cellimm.2017.01.004. Epub 2017 Jan 5.

PMID:
28089340
6.

Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor.

Le Noci V, Sommariva M, Tortoreto M, Zaffaroni N, Campiglio M, Tagliabue E, Balsari A, Sfondrini L.

Oncoimmunology. 2016 Sep 20;5(11):e1234571. doi: 10.1080/2162402X.2016.1234571. eCollection 2016.

7.

Expression and prognostic significance of the autoimmune regulator gene in breast cancer cells.

Bianchi F, Sommariva M, De Cecco L, Triulzi T, Romero-Cordoba S, Tagliabue E, Sfondrini L, Balsari A.

Cell Cycle. 2016 Dec;15(23):3220-3229. Epub 2016 Oct 18.

8.

CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts.

De Cesare M, Sfondrini L, Pennati M, De Marco C, Motta V, Tagliabue E, Deraco M, Balsari A, Zaffaroni N.

J Transl Med. 2016 Jan 25;14:25. doi: 10.1186/s12967-016-0781-4.

9.

miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response.

Cataldo A, Cheung DG, Balsari A, Tagliabue E, Coppola V, Iorio MV, Palmieri D, Croce CM.

Oncotarget. 2016 Jan 5;7(1):786-97. doi: 10.18632/oncotarget.6381.

10.

Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.

Di Modica M, Sfondrini L, Regondi V, Varchetta S, Oliviero B, Mariani G, Bianchi GV, Generali D, Balsari A, Triulzi T, Tagliabue E.

Oncotarget. 2016 Jan 5;7(1):255-65. doi: 10.18632/oncotarget.6353.

11.

Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment.

Le Noci V, Tortoreto M, Gulino A, Storti C, Bianchi F, Zaffaroni N, Tripodo C, Tagliabue E, Balsari A, Sfondrini L.

Oncoimmunology. 2015 May 27;4(10):e1040214. eCollection 2015 Oct.

12.

Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration.

Triulzi T, De Cecco L, Sandri M, Prat A, Giussani M, Paolini B, Carcangiu ML, Canevari S, Bottini A, Balsari A, Menard S, Generali D, Campiglio M, Di Cosimo S, Tagliabue E.

Oncotarget. 2015 Sep 29;6(29):28173-82. doi: 10.18632/oncotarget.4405.

13.

Aerosol Delivery in the Treatment of Lung Cancer.

Storti C, Le Noci V, Sommariva M, Tagliabue E, Balsari A, Sfondrini L.

Curr Cancer Drug Targets. 2015;15(7):604-12. Review.

PMID:
26033086
14.

PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells.

Plantamura I, Casalini P, Dugnani E, Sasso M, D'Ippolito E, Tortoreto M, Cacciatore M, Guarnotta C, Ghirelli C, Barajon I, Bianchi F, Triulzi T, Agresti R, Balsari A, Campiglio M, Tripodo C, Iorio MV, Tagliabue E.

Mol Oncol. 2014 Jul;8(5):968-81. doi: 10.1016/j.molonc.2014.03.015. Epub 2014 Mar 27.

15.

Prognostic role of tumor size in T1 HER2-positive breast cancers treated with adjuvant trastuzumab.

Campiglio M, Sandri M, Sasso M, Bianchi F, Balsari A, Ménard S, Tagliabue E.

Ann Oncol. 2014 May;25(5):1073-4. doi: 10.1093/annonc/mdu058. Epub 2014 Feb 20. No abstract available.

PMID:
24558025
16.

Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis.

Cardani D, Sardi C, La Ferla B, D'Orazio G, Sommariva M, Marcucci F, Olivero D, Tagliabue E, Koepsell H, Nicotra F, Balsari A, Rumio C.

Mol Cancer. 2014 Feb 5;13:23. doi: 10.1186/1476-4598-13-23.

17.

Maspin influences response to doxorubicin by changing the tumor microenvironment organization.

Triulzi T, Ratti M, Tortoreto M, Ghirelli C, Aiello P, Regondi V, Di Modica M, Cominetti D, Carcangiu ML, Moliterni A, Balsari A, Casalini P, Tagliabue E.

Int J Cancer. 2014 Jun 15;134(12):2789-97. doi: 10.1002/ijc.28608. Epub 2013 Nov 30.

18.

Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study.

Campiglio M, Bufalino R, Sasso M, Ferri E, Casalini P, Adamo V, Fabi A, Aiello R, Riccardi F, Valle E, Scotti V, Tabaro G, Giuffrida D, Tarenzi E, Bologna A, Mustacchi G, Bianchi F, Balsari A, Ménard S, Tagliabue E.

Breast Cancer Res Treat. 2013 Aug;141(1):101-10. doi: 10.1007/s10549-013-2658-z. Epub 2013 Aug 13.

19.

Increased sensitivity to chemotherapy induced by CpG-ODN treatment is mediated by microRNA modulation.

De Cecco L, Berardi M, Sommariva M, Cataldo A, Canevari S, Mezzanzanica D, Iorio MV, Tagliabue E, Balsari A.

PLoS One. 2013;8(3):e58849. doi: 10.1371/journal.pone.0058849. Epub 2013 Mar 6.

20.

Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress.

Triulzi T, Casalini P, Sandri M, Ratti M, Carcangiu ML, Colombo MP, Balsari A, Ménard S, Orlandi R, Tagliabue E.

PLoS One. 2013;8(2):e56761. doi: 10.1371/journal.pone.0056761. Epub 2013 Feb 18.

21.

High efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors.

Sommariva M, de Cesare M, Meini A, Cataldo A, Zaffaroni N, Tagliabue E, Balsari A.

J Transl Med. 2013 Jan 29;11:25. doi: 10.1186/1479-5876-11-25.

22.

Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases.

Sfondrini L, Sommariva M, Tortoreto M, Meini A, Piconese S, Calvaruso M, Van Rooijen N, Bonecchi R, Zaffaroni N, Colombo MP, Tagliabue E, Balsari A.

Int J Cancer. 2013 Jul 15;133(2):383-93. doi: 10.1002/ijc.28028. Epub 2013 Feb 12.

23.

Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34⁺ cells in a xenograft model.

Rossini A, Giussani M, Giacomini A, Guarnotta C, Tagliabue E, Balsari A.

Breast Cancer Res Treat. 2012 Nov;136(2):457-67. doi: 10.1007/s10549-012-2281-4. Epub 2012 Oct 11.

24.

EGFR through STAT3 modulates ΔN63α expression to sustain tumor-initiating cell proliferation in squamous cell carcinomas.

Ripamonti F, Albano L, Rossini A, Borrelli S, Fabris S, Mantovani R, Neri A, Balsari A, Magnifico A, Tagliabue E.

J Cell Physiol. 2013 Apr;228(4):871-8. doi: 10.1002/jcp.24238.

PMID:
23018838
25.

PET prediction of response to trastuzumab in ErbB2-positive human xenograft model.

Tagliabue E, Campiglio M, Balsari A, Ménard S.

J Nucl Med. 2012 Oct;53(10):1654-5; author reply 1655-6. doi: 10.2967/jnumed.112.108068. Epub 2012 Aug 23. No abstract available.

26.

Modulation of DNA repair genes induced by TLR9 agonists: A strategy to eliminate "altered" cells?

Sommariva M, De Cecco L, Tagliabue E, Balsari A.

Oncoimmunology. 2012 Mar 1;1(2):258-259.

27.

Influence of fatty acid-free diet on mammary tumor development and growth rate in HER-2/Neu transgenic mice.

Rossini A, Zanobbio L, Sfondrini L, Cavalleri A, Secreto G, Morelli D, Palazzo M, Sommariva M, Tagliabue E, Rumio C, Balsari A.

J Cell Physiol. 2013 Jan;228(1):242-9. doi: 10.1002/jcp.24130.

PMID:
22689438
28.

FOXP3 expression in tumor cells and implications for cancer progression.

Triulzi T, Tagliabue E, Balsari A, Casalini P.

J Cell Physiol. 2013 Jan;228(1):30-5. doi: 10.1002/jcp.24125. Review.

PMID:
22674548
29.

The HER2 World: Better Treatment Selection for Better Outcome.

Tagliabue E, Campiglio M, Pupa SM, Balsari A, Ménard S.

J Natl Cancer Inst Monogr. 2011;2011(43):82-5. doi: 10.1093/jncimonographs/lgr041.

PMID:
22043048
30.

TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects.

Sommariva M, De Cecco L, De Cesare M, Sfondrini L, Ménard S, Melani C, Delia D, Zaffaroni N, Pratesi G, Uva V, Tagliabue E, Balsari A.

Cancer Res. 2011 Oct 15;71(20):6382-90. doi: 10.1158/0008-5472.CAN-11-1285. Epub 2011 Aug 30.

31.

Activity and resistance of trastuzumab according to different clinical settings.

Tagliabue E, Campiglio M, Pupa SM, Ménard S, Balsari A.

Cancer Treat Rev. 2012 May;38(3):212-7. doi: 10.1016/j.ctrv.2011.06.002. Epub 2011 Jul 2. Review.

PMID:
21726959
32.

Induction of Paneth cell degranulation by orally administered Toll-like receptor ligands.

Rumio C, Sommariva M, Sfondrini L, Palazzo M, Morelli D, Viganò L, De Cecco L, Tagliabue E, Balsari A.

J Cell Physiol. 2012 Mar;227(3):1107-13. doi: 10.1002/jcp.22830.

PMID:
21567398
33.

Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study.

Campiglio M, Bufalino R, Sandri M, Ferri E, Aiello RA, De Matteis A, Mottolese M, De Placido S, Querzoli P, Jirillo A, Bottini A, Fantini M, Bonetti A, Pedani F, Mauri M, Molino A, Ferro A, Pupa SM, Sasso M, Ménard S, Balsari A, Tagliabue E.

Breast Cancer Res Treat. 2011 Jul;128(1):147-54. doi: 10.1007/s10549-011-1484-4. Epub 2011 Apr 11.

PMID:
21479926
34.

Stimulation of TLRs by LMW-HA induces self-defense mechanisms in vaginal epithelium.

Dusio GF, Cardani D, Zanobbio L, Mantovani M, Luchini P, Battini L, Galli V, Diana A, Balsari A, Rumio C.

Immunol Cell Biol. 2011 Jul;89(5):630-9. doi: 10.1038/icb.2010.140. Epub 2010 Nov 23.

PMID:
21102537
35.

Dansyl C-glucoside as a novel agent against endotoxic shock.

La Ferla B, Spinosa V, D'Orazio G, Palazzo M, Balsari A, Foppoli AA, Rumio C, Nicotra F.

ChemMedChem. 2010 Oct 4;5(10):1677-80. doi: 10.1002/cmdc.201000282. No abstract available.

PMID:
20726031
36.

Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors.

Lucci MA, Orlandi R, Triulzi T, Tagliabue E, Balsari A, Villa-Moruzzi E.

Cell Oncol. 2010;32(5-6):361-72. doi: 10.3233/CLO-2010-0520.

37.

HER2 as a target for breast cancer therapy.

Tagliabue E, Balsari A, Campiglio M, Pupa SM.

Expert Opin Biol Ther. 2010 May;10(5):711-24. doi: 10.1517/14712591003689972. Review.

PMID:
20214497
38.

Influence of lignans depletion on murine mammary gland morphology.

Rossini A, Zanobbio L, Palazzo M, Sfondrini L, Morelli D, Tagliabue E, Balsari A, Rumio C.

Nutr Cancer. 2010;62(2):237-42. doi: 10.1080/01635580903305284.

PMID:
20099198
39.

Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN.

De Cesare M, Sfondrini L, Campiglio M, Sommariva M, Bianchi F, Perego P, van Rooijen N, Supino R, Rumio C, Zunino F, Pratesi G, Tagliabue E, Balsari A.

J Immunother. 2010 Jan;33(1):8-15. doi: 10.1097/CJI.0b013e3181affaa7.

PMID:
19952960
40.

Intestinal glucose uptake protects liver from lipopolysaccharide and D-galactosamine, acetaminophen, and alpha-amanitin in mice.

Zanobbio L, Palazzo M, Gariboldi S, Dusio GF, Cardani D, Mauro V, Marcucci F, Balsari A, Rumio C.

Am J Pathol. 2009 Sep;175(3):1066-76. doi: 10.2353/ajpath.2009.090071. Epub 2009 Aug 21.

41.

Toll-like receptors 3, 4, and 7 are expressed in the enteric nervous system and dorsal root ganglia.

Barajon I, Serrao G, Arnaboldi F, Opizzi E, Ripamonti G, Balsari A, Rumio C.

J Histochem Cytochem. 2009 Nov;57(11):1013-23. doi: 10.1369/jhc.2009.953539. Epub 2009 Jun 22.

42.

FOXP3 expression and overall survival in breast cancer.

Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Mènard S, Tagliabue E, Balsari A.

J Clin Oncol. 2009 Apr 10;27(11):1746-52. doi: 10.1200/JCO.2008.17.9036. Epub 2009 Mar 2.

PMID:
19255331
43.

Critical role of TLR9 in acute graft-versus-host disease.

Calcaterra C, Sfondrini L, Rossini A, Sommariva M, Rumio C, Ménard S, Balsari A.

J Immunol. 2008 Nov 1;181(9):6132-9.

44.

Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy.

De Cesare M, Calcaterra C, Pratesi G, Gatti L, Zunino F, Mènard S, Balsari A.

Clin Cancer Res. 2008 Sep 1;14(17):5512-8. doi: 10.1158/1078-0432.CCR-08-0445.

45.

Sodium-dependent glucose transporter-1 as a novel immunological player in the intestinal mucosa.

Palazzo M, Gariboldi S, Zanobbio L, Selleri S, Dusio GF, Mauro V, Rossini A, Balsari A, Rumio C.

J Immunol. 2008 Sep 1;181(5):3126-36. Erratum in: J Immunol. 2008 Nov 15;181(10):7428.

46.

Low molecular weight hyaluronic acid increases the self-defense of skin epithelium by induction of beta-defensin 2 via TLR2 and TLR4.

Gariboldi S, Palazzo M, Zanobbio L, Selleri S, Sommariva M, Sfondrini L, Cavicchini S, Balsari A, Rumio C.

J Immunol. 2008 Aug 1;181(3):2103-10.

47.

Induction of pro-inflammatory programs in enteroendocrine cells by the Toll-like receptor agonists flagellin and bacterial LPS.

Selleri S, Palazzo M, Deola S, Wang E, Balsari A, Marincola FM, Rumio C.

Int Immunol. 2008 Aug;20(8):961-70. doi: 10.1093/intimm/dxn055. Epub 2008 Jun 10.

PMID:
18544573
48.

Biology, prognosis and response to therapy of breast carcinomas according to HER2 score.

Ménard S, Balsari A, Tagliabue E, Camerini T, Casalini P, Bufalino R, Castiglioni F, Carcangiu ML, Gloghini A, Scalone S, Querzoli P, Lunardi M, Molino A, Mandarà M, Mottolese M, Marandino F, Venturini M, Bighin C, Cancello G, Montagna E, Perrone F, De Matteis A, Sapino A, Donadio M, Battelli N, Santinelli A, Pavesi L, Lanza A, Zito FA, Labriola A, Aiello RA, Caruso M, Zanconati F, Mustacchi G, Barbareschi M, Frisinghelli M, Russo R, Carrillo G; OMERO Group.

Ann Oncol. 2008 Oct;19(10):1706-12. doi: 10.1093/annonc/mdn369. Epub 2008 Jun 9.

PMID:
18544559
49.

Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu.

Pratesi G, Petrangolini G, Tortoreto M, Addis A, Zunino F, Calcaterra C, Merlo A, Tagliabue E, Menard S, Balsari A.

J Immunother. 2008 Jul-Aug;31(6):537-44. doi: 10.1097/CJI.0b013e31817c37ff.

PMID:
18528301
50.

Cross-talk among Toll-like receptors and their ligands.

Palazzo M, Gariboldi S, Zanobbio L, Dusio GF, Selleri S, Bedoni M, Balsari A, Rumio C.

Int Immunol. 2008 May;20(5):709-18. doi: 10.1093/intimm/dxn027. Epub 2008 Apr 7.

PMID:
18397908

Supplemental Content

Loading ...
Support Center